These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17575575)

  • 1. Side effects and complications. Tesamorelin--results from Phase III.
    TreatmentUpdate; 2007; 19(3):6-7. PubMed ID: 17575575
    [No Abstract]   [Full Text] [Related]  

  • 2. Complications & side effects. Can TH9057 reduce fat deposits?
    TreatmentUpdate; 2004; 16(7):3. PubMed ID: 17219684
    [No Abstract]   [Full Text] [Related]  

  • 3. Side effects and complications. Clinical trials of tesamorelin in Canada.
    TreatmentUpdate; 2007; 19(3):7. PubMed ID: 17571443
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.
    Falutz J; Mamputu JC; Potvin D; Moyle G; Soulban G; Loughrey H; Marsolais C; Turner R; Grinspoon S
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4291-304. PubMed ID: 20554713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The next generation of human growth hormone. How Serostim and tesamorelin measure up.
    Grodeck B
    Posit Aware; 2008; 19(5):28-32. PubMed ID: 18828236
    [No Abstract]   [Full Text] [Related]  

  • 6. Tesamorelin for fat accumulation. 52-week effects and safety of tesamorelin (growth hormone releasing factor) in HIV patients with fat accumulation.
    Berger D
    Posit Aware; 2008; 19(3):31. PubMed ID: 18724445
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.
    Falutz J; Allas S; Mamputu JC; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S
    AIDS; 2008 Sep; 22(14):1719-28. PubMed ID: 18690162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
    Falutz J; Potvin D; Mamputu JC; Assaad H; Zoltowska M; Michaud SE; Berger D; Somero M; Moyle G; Brown S; Martorell C; Turner R; Grinspoon S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):311-22. PubMed ID: 20101189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complications and side effects. France: a large hospital database looks at heart attacks.
    TreatmentUpdate; 2009; 21(3):9-11. PubMed ID: 19623730
    [No Abstract]   [Full Text] [Related]  

  • 10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complications & side effects. HAART and bones-mixed messages.
    TreatmentUpdate; 2007; 19(4):3-5. PubMed ID: 17969257
    [No Abstract]   [Full Text] [Related]  

  • 12. Good results for lipodystrophy drug.
    AIDS Patient Care STDS; 2007 Feb; 21(2):146. PubMed ID: 17328664
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor.
    Tomlinson B
    Curr Opin Investig Drugs; 2006 Oct; 7(10):936-45. PubMed ID: 17086939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count.
    Stebbing J; Powles T; Bower M
    AIDS; 2008 Feb; 22(4):551-2. PubMed ID: 18301078
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of early initiation of highly active antiretroviral therapy on CD4 cell count and HIV-RNA viral load trends within 24 months of the onset of acute retroviral syndrome.
    Voirin N; Routy JP; Smith D; Baratin D; Trépo C; Cotte L; Touraine JL; Livrozet JM; Cooper DA; Ritter J; André P; Vanhems P
    HIV Med; 2008 Jul; 9(6):440-4. PubMed ID: 18705761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects and complications. Stimulating growth hormone.
    TreatmentUpdate; 2007; 19(3):6. PubMed ID: 17571442
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
    Durier C; Capitant C; Lascaux AS; Goujard C; Oksenhendler E; Poizot-Martin I; Viard JP; Weiss L; Netzer E; Delfraissy JF; Aboulker JP; Lévy Y
    AIDS; 2007 Sep; 21(14):1887-97. PubMed ID: 17721096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brazilian HIV-infected population: assessment of the needs of endodontic treatment in the post-highly active antiretroviral therapy era.
    de Brito LC; da Rosa MA; Lopes VS; e Ferreira EF; Vieira LQ; Sobrinho AP
    J Endod; 2009 Sep; 35(9):1178-81. PubMed ID: 19720212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
    Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.